<div id="readability-page-1"><p><span>Progyny (NASDAQ:PGNY - Get Free Report)</span> was downgraded by equities research analysts at Wall Street Zen from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a note issued to investors on Saturday.</p><ul><li>3 Best Stocks to Buy That You’ve Probably Never Heard Of</li></ul><p>Several other research firms have also commented on PGNY. KeyCorp upgraded shares of Progyny from a &#34;sector weight&#34; rating to an &#34;overweight&#34; rating and set a $30.00 price objective for the company in a research note on Tuesday, November 11th. Canaccord Genuity Group upped their target price on Progyny from $23.00 to $26.00 and gave the company a &#34;hold&#34; rating in a report on Monday, November 17th. JPMorgan Chase &amp; Co. increased their price target on Progyny from $25.00 to $26.00 and gave the company a &#34;neutral&#34; rating in a research report on Tuesday, November 11th. Barclays initiated coverage on Progyny in a research report on Monday, December 8th. They issued an &#34;overweight&#34; rating and a $29.00 price objective on the stock. Finally, Weiss Ratings  restated a &#34;hold (c)&#34; rating on shares of Progyny in a research note on Monday. One research analyst  has rated the stock with a Strong Buy rating, six have issued  a Buy rating and four have issued  a Hold rating to the company. Based on data from MarketBeat.com, Progyny presently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $27.50.</p><p><b>Check Out Our Latest Stock Report on Progyny</b></p><h2>Progyny Trading Up 1.8%</h2><p>NASDAQ PGNY opened at $26.63 on Friday. The business has a fifty day simple moving average of $23.08 and a 200 day simple moving average of $22.55. Progyny has a 12 month low of $13.96 and a 12 month high of $27.51. The firm has a market capitalization of $2.30 billion, a P/E ratio of 42.27, a PEG ratio of 2.06 and a beta of 0.97. </p><p>Progyny (NASDAQ:PGNY - Get Free Report) last posted its quarterly earnings data on Thursday, November 6th. The company reported $0.45 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.39 by $0.06. The firm had revenue of $313.35 million for the quarter, compared to the consensus estimate of $299.23 million. Progyny had a net margin of 4.46% and a return on equity of 10.71%. The business's revenue for the quarter was up 9.3% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.11 EPS. Progyny has set its FY 2025 guidance at 1.790-1.820 EPS and its Q4 2025 guidance at 0.370-0.400 EPS.  As a group, sell-side analysts predict that  Progyny will post 0.6 EPS for the current fiscal year. </p><h2>Insiders Place Their Bets</h2><p>In other news, CEO Peter Anevski bought 79,500 shares of the stock in a transaction on Thursday, November 13th. The shares were purchased at an average cost of $24.29 per share, for a total transaction of $1,931,055.00. Following the completion of the purchase, the chief executive officer directly owned 680,251 shares in the company, valued at $16,523,296.79. This represents a 13.23% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Mark S. Livingston sold 21,303 shares of the company's stock in a transaction on Monday, November 17th. The shares were sold at an average price of $25.50, for a total value of $543,226.50. Following the transaction, the chief financial officer directly owned 48,358 shares in the company, valued at $1,233,129. This represents a 30.58% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 22,046 shares of company stock valued at $561,691 over the last three months. Company insiders own  9.40% of the company's stock. </p><h2>Hedge Funds Weigh In On Progyny</h2><p>Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Nordea Investment Management AB grew its stake in  Progyny by 0.6% in the 2nd quarter. Nordea Investment Management AB now owns 183,362 shares of the company's stock valued at $4,052,000 after buying an additional 1,140 shares in the last quarter.  Cresset Asset Management LLC lifted its position in shares of  Progyny by 715.3% during the second quarter. Cresset Asset Management LLC now owns 85,053 shares of the company's stock worth $1,871,000 after acquiring an additional 74,621 shares in the last quarter.  Voya Investment Management LLC boosted its holdings in shares of  Progyny by 258.2% in the first quarter. Voya Investment Management LLC now owns 185,495 shares of the company's stock worth $4,144,000 after acquiring an additional 133,703 shares during the period.  Millennium Management LLC grew its position in shares of  Progyny by 7.5% in the first quarter. Millennium Management LLC now owns 1,302,890 shares of the company's stock valued at $29,107,000 after purchasing an additional 90,367 shares in the last quarter.  Finally, Acadian Asset Management LLC raised its stake in shares of  Progyny by 243.6% during the 1st quarter. Acadian Asset Management LLC now owns 205,650 shares of the company's stock valued at $4,589,000 after purchasing an additional 145,802 shares during the period. Institutional investors own  94.93% of the company's stock. </p><h2>About Progyny</h2> (Get Free Report)<p>Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company's digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.  </p><p>The core of Progyny's offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.</p><h2>See Also</h2><ul><li>Five stocks we like better than Progyny</li><li>How to Invest in Tech Stocks and Top Tech Stocks to Consider</li><li>Nike Beats on Earnings But Struggles in China and Faces Tariffs</li><li>Low PE Growth Stocks: Unlocking Investment Opportunities</li><li>Is the AI Boom a Bubble? These 2 Dividend Stocks Say No</li><li>What Does a Gap Up Mean in Stocks? How to Play the Gap</li><li>4 High-Potential ETFs for 2026: Small Caps, Space Stocks, and More</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UEdOWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="330" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UEdOWQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Progyny Right Now?</h2><p>Before you consider Progyny, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Progyny wasn't on the list.</p><p>While Progyny currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

PGNY

<p>Wall Street Zen downgraded Progyny (NASDAQ:PGNY) from a "buy" to a "hold" rating. Other analysts have mixed ratings, with KeyCorp upgrading to "overweight" and Canaccord Genuity maintaining a "hold." Progyny's stock opened at $26.63, with a market cap of $2.30 billion. Recent insider transactions include CEO Peter Anevski buying shares and CFO Mark S. Livingston selling shares. Institutional investors have adjusted their stakes in the company.</p>

Wall Street Zen Downgrades Progyny (NASDAQ:PGNY) to Hold